Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
1.140
+0.020 (1.79%)
At close: Jun 26, 2026, 4:00 PM EDT
1.130
-0.010 (-0.88%)
After-hours: Jun 26, 2026, 7:50 PM EDT

Company Description

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia.

The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.

It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules.

In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics.

Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing.

Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Bionano Genomics, Inc.
Bionano Genomics logo
Country United States
Founded 2003
IPO Date Aug 21, 2018
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 97
CEO Albert Luderer

Contact Details

Address:
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
United States
Phone 858 888 7600
Website bionano.com

Stock Details

Ticker Symbol BNGO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001411690
CUSIP Number 09075F404
ISIN Number US09075F4046
Employer ID 26-1756290
SIC Code 3826

Key Executives

Name Position
Dr. Albert A. Luderer Ph.D. Chairman, Interim Chief Executive Officer, Interim President and Interim Principal Financial Officer
Mark Oldakowski Chief Operating Officer
Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer
Mark Adamchak CPA Vice President of Accounting, Principal Accounting Officer and Controller
Jonathan Dixon J.D. General Counsel and Secretary
Cory Kreeck Global Head of People Operations

Latest SEC Filings

Date Type Title
Jun 24, 2026 8-K Current Report
Jun 5, 2026 8-K Current Report
May 28, 2026 8-K Current Report
May 14, 2026 8-K Current Report
May 13, 2026 10-Q Quarterly Report
May 13, 2026 8-K Current Report
May 8, 2026 S-3 Registration statement under Securities Act of 1933
May 6, 2026 8-K Current Report
Apr 2, 2026 ARS Filing
Apr 2, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material